

10/520902

Wiggin and Dana LLP
One City Place
185 Asylum Street
Hartford, Connecticut
06103-3402

860.297.3700
860.525.9380 fax
www.wiggin.com

RECEIVED
CENTRAL FAX CENTER

JAN 19 2007

Certificate

JAN 30 2007

of Correction

WIGGIN AND DANA

Counsellors at Law

Telefax Transmittal

Date:
January 19, 2007

To / Company / Telefax:
Attention: Certificate of Correction Branch / U. S. Patent Office /
571.273.8300

From:
Todd E. Garabedian, Ph.D.

Telephone / Email:
860.297.3716 / tgarabedian@wiggin.com

Client / matter code:
10706 / 97

Please copy:

We will copy:

Special Instructions

RE: U. S. Patent No. 7,153,997 B2
Attorney Docket No: 102698-102

Dear Sir: Please check the contents attached herewith and verify that the following items were enclosed by sending confirmation to the above-noted facsimile number.

- Letter Re: Certificate of Correction (3 pages)
- Certificate of Correction Form PTO/SB/44 (1 Page)

Please issue the requested Certificate of Correction to correct the last name of the third named inventor, and to correct a minor typographical error, as set forth in the attached Letter and Certificate. Please do not hesitate to contact me if you have any questions.

Thank you.

4 page(s) following this page

JAN 30 2007

USPTO - Please
discard previous fax
Received by USPTO on
1/19/2007 9:39 AM (EST)
and substitute this
Fax Request.
Thank you.

This message is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this message is not the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error please notify us immediately by telephone and return the original message to us by mail. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED
CENTRAL FAX CENTER

In re Patent No. : 7,153,997 B2
Issue Date : December 26, 2006
Based on Application of : NEERAJ GARG, ET AL.
Serial No. : 10/520,902
Filed : January 7, 2005
For : NOVEL COMPOUNDS
Examiner : S. Kumar
Attorney Docket : 102698-102
Group Art Unit : 1621
Confirmation No. : 4807
Customer No. : 27267

JAN 19 2007

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via telephone number (571) 273-8300, addressed to:
Certificate of Correction Branch, Commissioner for Patents, on 19 JAN 2007.

By

Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Patentee

LETTER RE: CERTIFICATE OF CORRECTION
SUBMITTED UNDER 37 CFR §1.323

Certificate of Correction Branch
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Patentees submit herewith a Form PTO/SB/44 to correct the name of the third named inventor of the above-identified U. S. Patent.

On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."

JAN 30 2007

U. S. Patent No. 7,153,997 B2
Issue Date: December 26, 2006

By Notice of Recordation of Assignment Document dated December 4, 2006, the USPTO notified Patentees that inventor Norin's name had been corrected in the Assignment at Reel **018579, Frame 0678.**

Additionally, a minor mistake of a clerical or typographical nature in the above-identified U.S. Patent is noted in the second line of claim 7 at column 39 of the Patent. The last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent
selected from the group consisting of an aP2 inhibitor, a".

Patentees submit that the above-noted name correction and minor typographical error occurred in good faith, and that the proposed corrections do not involve changes in the above-identified patent as would constitute new matter or would require re-examination. Accordingly, Patentees respectfully request that a Certificate of Correction be issued.

The \$100 Certificate of Correction Fee, as required under 37 CFR §1.20(a), as well as any other charges associated with this request, may be charged to Deposit Account 23-1665. Two copies of this request are enclosed.

JAN 30 2007

U. S. Patent No. 7,153,997 B2
Issue Date: December 26, 2006

If the Office requires any additional information, kindly contact Patentees' representative
at the telephone number below.

Respectfully submitted,

NEERAJ GARG, ET AL.

Date: 19 JAN 2007

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Attorney for Patentees
Registration No. 39,197

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Facsimile: (203) 782-2889

\\10706\\97154908.1

JAN 30 2007

PTO/SB/44 (02-01)

Approved for use through 01/31/2004. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,153,997 B2

DATED : December 26, 2006

INVENTOR(S) : Neeraj Garg, Mahmoud Rahimi Ghadim, Thomas Anders Wilson Norin, Lars
Johan Malm and Denis Evan Ryono

It is certified that error appears in the above-identified patent and that said Letters Patent
is hereby corrected as shown below:

1. On the cover page of the Patent, at item (75) "Inventors", the name of the third named
inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders
Wilson Norin."

2. In the second line of claim 7 at column 39 of the Patent, the last word in column 39, "is",
should be deleted from the second line of claim 7. The second and third lines of claim 7 will
then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent
selected from the group consisting of an aP2 inhibitor, a".

MAILING ADDRESS OF SENDER:

Todd E. Garabedian, Ph.D.
Wiggin & Dana LLP
P. O. Box 1832

New Haven, CT 06508-1832

PATENT NO. 7,153,997 B2

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the
amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WD#54910

JAN 30 2007

JAN 19 2007

Wiggin and Dana LLP
One City Place
185 Asylum Street
Hartford, Connecticut
06103-3402

860.297.3700
860.525.9380 fax
www.wiggin.com

Certificate
JAN 30 2007
of Correction

WIGGIN AND DANA
Counsellors at Law

Telefax Transmittal

Date:

January 19, 2007

To / Company / Telefax:

Attention: Certificate of Correction Branch / U. S. Patent Office /
571.273.8300

From:

Todd E. Garabedian, Ph.D.

Telephone / Email:

860.297.3716 / tgarabedian@wiggin.com

Client / matter code:

10706 / 97

Please copy:

We will copy:

Special Instructions

RE: U. S. Patent No. 7,153,997 B2
Attorney Docket No: 102698-102

Dear Sir: Please check the contents attached herewith and verify that the following items were enclosed by sending confirmation to the above-noted facsimile number.

- Letter Re: Certificate of Correction (3 pages)
- Certificate of Correction Form PTO/SB/44 (1 Page)

Please issue the requested Certificate of Correction to correct the last name of the third named inventor, and to correct a minor typographical error, as set forth in the attached Letter and Certificate. Please do not hesitate to contact me if you have any questions.

Thank you.

JAN 30 2007

4 page(s) following this page

RECEIVED
CENTRAL FAX CENTER

JAN 19 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent No. : 7,153,997 B2
Issue Date : December 26, 2006
Based on Application of : NEERAJ GARG, ET AL.
Serial No. : 10/520,902
Filed : January 7, 2005
For : NOVEL COMPOUNDS
Examiner : S. Kumar
Attorney Docket : 102698-102
Group Art Unit : 1621
Confirmation No. : 4807
Customer No. : 27267

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via telephone number (571) 273-8300, addressed to: Certificate of Correction Branch, Commissioner for Patents, on 19 JAN 2007.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Patentee

LETTER RE: CERTIFICATE OF CORRECTION
SUBMITTED UNDER 37 CFR §1.323

Certificate of Correction Branch
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Patentees submit herewith a Form PTO/SB/44 to correct the name of the third named inventor of the above-identified U. S. Patent.

On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."

JAN 30 2007

U. S. Patent No. 7,153,997 B2
Issue Date: December 26, 2006

By Notice of Recordation of Assignment Document dated December 4, 2006, the USPTO notified Patentees that inventor Norin's name had been corrected in the Assignment at Reel 018579, Frame 0678.

Additionally, a minor mistake of a clerical or typographical nature in the above-identified U.S. Patent is noted in the second line of claim 7 at column 39 of the Patent. The last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent
selected from the group consisting of an aP2 inhibitor, a".

Patentees submit that the above-noted name correction and minor typographical error occurred in good faith, and that the proposed corrections do not involve changes in the above-identified patent as would constitute new matter or would require re-examination. Accordingly, Patentees respectfully request that a Certificate of Correction be issued.

The \$100 Certificate of Correction Fee, as required under 37 CFR §1.20(a), as well as any other charges associated with this request, may be charged to Deposit Account 23-1665. Two copies of this request are enclosed.

JAN 30 2007

U. S. Patent No. 7,153,997 B2
Issue Date: December 26, 2006


If the Office requires any additional information, kindly contact Patentees' representative
at the telephone number below.

Respectfully submitted,

NEERAJ GARG, ET AL.

Date: 19 JAN 2007

By:



Todd E. Garabedian, Ph.D.
Attorney for Patentees
Registration No. 39,197

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Facsimile: (203) 782-2889

\\10706\\97154908.1

JAN 30 2007

PTO/SB/44 (02-01)

Approved for use through 01/31/2004. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,153,997 B2

DATED : December 26, 2006

INVENTOR(S) : Neeraj Garg, Mahmoud Rahimi Ghadim, Thomas Anders Wilson Norin, Lars
Johan Malm and Denis Evan Ryono

It is certified that error appears in the above-identified patent and that said Letters Patent
is hereby corrected as shown below:

1. On the cover page of the Patent, at item (75) "Inventors", the name of the third named
inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders
Wilson Norin."

2. In the second line of claim 7 at column 39 of the Patent, the last word in column 39, "ls",
should be deleted from the second line of claim 7. The second and third lines of claim 7 will
then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent
selected from the group consisting of an aP2 inhibitor, a".

JAN 30 2007

MAILING ADDRESS OF SENDER:

Todd E. Garabedian, Ph.D.
Wiggin & Dana LLP
P. O. Box 1832

New Haven, CT 06508-1832

PATENT NO. 6,633,175 B1

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the
amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WD#54910